U.S. Food and Drug Administration advisors have recommended FDA approval for Pfizer's COVID-19 vaccines for children aged 5 to 11.
The advisory panel voted unanimously, saying that the benefits of vaccination outweigh the risks.
Last week, Pfizer said the vaccine showed 90.7 percent efficacy in a clinical trial.
Participants were given a dose one-third of that given to kids aged 12 and up.
A final green light will open the door for some 28 million children to get vaccinated.
And inoculations may begin as soon as next week, once the FDA and the U.S. Centers for Disease Control and Prevention make the final call.